← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS › BLOOD AND RELATED PRODUCTS › Blood substitutes and plasma protein fractions
dextran
B05AA05
Forms & Strengths
- Dextran 40: 10% solution in 0.9% sodium chloride or 5% dextrose (500 mL)
- Dextran 70: 6% solution in 0.9% sodium chloride (500 mL)
Adult Dosing
- Hypovolemic shock: Initial 500 mL rapidly (over 15-30 minutes); total daily dose should not exceed 20 mL/kg (approx. 1500 mL)
- Prophylaxis of thromboembolism (surgical): 500 mL (approx. 10 g) during surgery, then 500 mL daily for 2 to 3 days, then 500 mL every 2 to 3 days up to 2 weeks
Pediatric Dosing
- Hypovolemic shock: Total dose should not exceed 20 mL/kg
- Safety and efficacy in children are not well established; use only if potential benefits outweigh risks
Indications
- Adjunctive treatment in shock due to hemorrhage, surgery, trauma, or burns
- Prophylaxis of venous thrombosis and pulmonary embolism in high-risk surgical procedures
Mechanism of Action
- Colloidal volume expander that increases plasma volume by oncotic pressure, drawing fluid from the interstitial space into the intravascular compartment
- Improves microcirculatory blood flow by decreasing blood viscosity and inhibiting erythrocyte aggregation
Contraindications
- Known hypersensitivity to dextrans
- Severe bleeding disorders or marked hemostatic defects (e.g., severe thrombocytopenia, hypofibrinogenemia)
- Severe congestive heart failure and renal failure with oliguria or anuria
Adverse Reactions
- Anaphylactoid reactions (hypotension, urticaria, wheezing, angioedema)
- Circulatory overload and pulmonary edema
- Acute renal failure (osmotic nephrosis)
- Prolonged bleeding time and transient reductions in platelet count and fibrinogen levels
Drug Interactions
- Anticoagulants (heparin, warfarin): Increased risk of hemorrhage due to additive effects on hemostasis
- Vitamins and certain blood products: May interfere with blood typing and cross-matching
Curated Content: Needs Vetting Before Put to Clinical Use